Claim Missing Document
Check
Articles

Found 2 Documents
Search

Pemphigus Vulgaris Combination Adjuvant Therapy of Systemic Corticosteroid with Sparing Agent Sodium Mycophenolate Nopriyati; Antonius, Cayadi Sidarta; Budiamal, Susanti; Aryani, Inda Astri
Archives of The Medicine and Case Reports Vol. 1 No. 1 (2020): Archives of The Medicine and Case Reports
Publisher : Hanif Medisiana Publisher - Faculty of Medicine Universitas Sriwijaya

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.37275/amcr.v1i1.1

Abstract

Pemphigus Vulgaris (PV) is an autoimmune disease characterized by vesicles and bullae on the skin and mucosa resulting from an autoantibody reaction to desmosomal adhesion molecules desmoglein (Dsg) 1 and 3, which function as strong adhesions between keratinocytes. Pemphigus Vulgaris is more common in the fifth and sixth decades of age. The lesions are fragile blisters on the mucosa and skin. Diagnosing PV requires anamnesis, physical examination, and investigations such as histopathologic examination and direct immunofluorescence. Therapy generally uses steroids. Adjuvant treatment is given to reduce the side effects of corticosteroids. We reported a male, 59 years old, was treated with blisters that break easily into blisters on the head, face, chest, back, groin and buttocks accompanied by burning and itching. In the scalp, facial, anterior et posterior trunk, inguinal, and gluteal regions, multiple erythematous macules were found with lenticular-plaque shape; it was partially confluent with thick brown crusts which were challenging to remove. The histopathologic examination found the presence of suprabasal bullae with lymphocyte inflammation cells. The patient was diagnosed with PV and treated with corticosteroids with the sparing agent mycophenolate sodium and showed clinical improvement. The first-line treatment for pemphigus Vulgaris is systemic corticosteroids. Adjuvant sparing agent therapy is given to reduce the side effects of corticosteroids. Sodium mycophenolate sparing agent was selected because of its minimum side effects. In systemic management, the dose of corticosteroid and sparing agent mycophenolate sodium was gradually decreased. The patient experienced initial remission after treatment
Management of diabetic foot ulcers: dermatology perspective Daryago, Adi Agung Anantawijaya; Fitriani, Fitriani; Kartowigno, Soenarto; Aryani, Inda Astri; Yahya, Yulia Farida; Diba, Sarah; Stephanie, Aurelia
Bali Dermatology and Venereology Journal Vol 4, No 2 (2021)
Publisher : DiscoverSys Inc

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.15562/bdv.v4i2.65

Abstract

Diabetes mellitus (DM) is a chronic and complex disease that affects various parts of the body. It can lead to multiple systemic complications and also cutaneous manifestation. Diabetic foot ulcer (DFU) is one of the most devastating complications of DM in dermatology. The main etiology is an increase in plasma glucose, risk factors, or comorbidities due to DM itself. Neglected DFU can lead to further complications, including high amputation and mortality rates; thus, the healing of ulcers is the main objective of the treatment. Management is divided into the standard of care and adjuvant therapies. This study aims to optimize DFU management, so it can provide proper treatment and prevent complications.